Plandai Biotechnology, Inc. (PLPL) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
1451 NORTH 200 EAST LOGAN, UT 98102 |
| State of Incorp. | |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2016 MRQ | 6/30/2015 | 6/30/2014 | 6/30/2013 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 34 | 157 | 499 | |||
| Cash and cash equivalent | 34 | 157 | 499 | |||
| Receivables | 17 | 435 | 14 | |||
| Inventory, net of allowances, customer advances and progress billings | 2 | 3 | 6 | |||
| Inventory | 2 | 3 | 6 | |||
| Other undisclosed current assets | 365 | |||||
| Total current assets: | 418 | 594 | 519 | |||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 8,010 | 8,856 | 7,925 | |||
| Other noncurrent assets | 1 | 151 | 381 | |||
| Other undisclosed noncurrent assets | 75 | 83 | 11 | |||
| Total noncurrent assets: | 8,086 | 9,090 | 8,316 | |||
| TOTAL ASSETS: | 8,505 | 9,683 | 8,835 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 316 | 143 | 516 | |||
| Interest and dividends payable | 289 | |||||
| Accrued liabilities | 40 | 93 | ||||
| Other undisclosed accounts payable and accrued liabilities | 28 | 103 | 423 | |||
| Debt | (14,526) | 18 | 104 | |||
| Derivative instruments and hedges, liabilities | 24 | 45 | ||||
| Due to related parties | 16 | 3 | ||||
| Other undisclosed current liabilities | 29,341 | 40 | 239 | |||
| Total current liabilities: | 15,147 | 227 | 904 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 11,637 | 9,174 | ||||
| Long-term debt, excluding current maturities | 11,637 | 9,174 | ||||
| Liabilities, other than long-term debt | 1,674 | 502 | ||||
| Deferred revenue and credits | 1,514 | |||||
| Due to related parties | 502 | |||||
| Other liabilities | 160 | |||||
| Other undisclosed noncurrent liabilities | 1,359 | 1,741 | ||||
| Total noncurrent liabilities: | 1,674 | 12,996 | 11,416 | |||
| Total liabilities: | 16,821 | 13,223 | 12,320 | |||
| Temporary equity, including noncontrolling interest | (856) | |||||
| Equity | ||||||
| Equity, attributable to parent, including: | (6,499) | (2,203) | (3,484) | |||
| Common stock | 16 | 13 | 11 | |||
| Common stock, value, subscriptions | 45 | 1,480 | ✕ | |||
| Additional paid in capital | 30,125 | 21,947 | 7,834 | |||
| Accumulated deficit | (36,309) | (25,957) | (10,904) | |||
| Other undisclosed equity, attributable to parent | (376) | 315 | (425) | |||
| Equity, attributable to noncontrolling interest | (1,818) | (1,337) | ||||
| Other undisclosed equity | 856 | |||||
| Total equity: | (8,317) | (3,539) | (2,628) | |||
| Other undisclosed liabilities and equity | 0 | |||||
| TOTAL LIABILITIES AND EQUITY: | 8,505 | 9,683 | 8,835 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2016 TTM | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|
| Revenues | 93 | 266 | 359 | ||
| Cost of revenue (Cost of Product and Service Sold) | (76) | (1,576) | (978) | ||
| Other undisclosed gross profit | 885 | 15 | |||
| Gross profit: | 17 | (425) | (604) | ||
| Operating expenses | (8,942) | (7,528) | (2,054) | ||
| Other operating expense, net (Other Expenses) | (459) | ||||
| Other undisclosed operating income | 76 | 459 | |||
| Operating loss: | (8,850) | (7,953) | (2,658) | ||
| Nonoperating expense | (1,223) | (7,580) | (310) | ||
| Other nonoperating expense | (292) | (310) | |||
| Interest and debt expense | (2) | (521) | (265) | ||
| Loss from continuing operations: | (10,075) | (16,055) | (3,233) | ||
| Loss before gain (loss) on sale of properties: | (10,075) | (16,055) | (3,233) | ||
| Net loss: | (10,075) | (16,055) | (3,233) | ||
| Net income attributable to noncontrolling interest | 490 | 480 | 780 | ||
| Other undisclosed net income (loss) attributable to parent | (488) | 41 | (515) | ||
| Net loss available to common stockholders, diluted: | (10,072) | (15,534) | (2,968) | ||
Comprehensive Income ($ in thousands)
| 3/31/2016 TTM | 6/30/2015 | 6/30/2014 | 6/30/2013 | ||
|---|---|---|---|---|---|
| Net loss: | (10,075) | (16,055) | (3,233) | ||
| Comprehensive loss: | (10,075) | (16,055) | (3,233) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 490 | 480 | (780) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (376) | 666 | 1,991 | ||
| Comprehensive loss, net of tax, attributable to parent: | (9,961) | (14,908) | (2,023) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.